Physician profile
Larry A Warmoth
NPI 1902891815
$5,732.10
in general payments reported to CMS, 2019-2025
38 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $522 · 2021: $723 · 2022: $672 · 2023: $916 · 2024: $998 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198 · Education: $25.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.33 |
| Education | $25.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,277.05 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals Lp | $868.02 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $351.05 | 2021-2025 | |
| Travere Therapeutics, INC. | $318.76 | 2024-2025 | Filspari |
| Akebia Therapeutics INC | $297.39 | 2020-2025 | Vafseo, Auryxia |
| Nuwellis, INC. | $273.65 | 2020-2021 | |
| Vifor Pharma, INC. | $258.04 | 2019-2024 | Veltassa |
| Calliditas Therapeutics US INC. | $244.48 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.10 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $162.99 | 2020-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $150.99 | 2019-2025 | Gattex |
| Novo Nordisk INC | $148.15 | 2019-2025 | Ozempic |
| Horizon Therapeutics Plc | $131.25 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $93.01 | 2019 | |
| Penumbra, INC. | $77.42 | 2022-2024 | Indigo System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $72.75 | 2020-2021 | |
| Amgen INC. | $70.16 | 2023-2024 | Krystexxa, Tavneos |
| Arbor Pharmaceuticals, INC. | $69.05 | 2020-2021 | |
| Dexcom, INC. | $62.94 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $55.86 | 2021-2023 | Qulipta |
| Alexion Pharmaceuticals, INC. | $49.32 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $46.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $44.56 | 2023-2025 | |
| Glaxosmithkline, LLC. | $41.98 | 2022-2023 | Benlysta |
| Veloxis Pharmaceuticals, INC. | $38.74 | 2023 | Envarsus |
| Scpharmaceuticals INC. | $35.21 | 2025 | |
| Daiichi Sankyo INC. | $33.37 | 2020-2022 | |
| Cormedix INC. | $30.64 | 2024 | Defencath |
| Abbott Laboratories | $28.54 | 2022-2023 | Freestyle Libre 3 |
| Globus Medical, INC. | $24.76 | 2025 | Senza |
| Ardelyx, INC. | $21.77 | 2024 | Ibsrela |
| Outset Medical INC | $20.85 | 2023 | |
| Mallinckrodt Hospital Products INC. | $19.34 | 2020 | |
| Abiomed | $19.23 | 2025 | |
| Chiesi USA, INC. | $17.30 | 2025 | Elfabrio |
| Ultragenyx Pharmaceutical INC. | $16.64 | 2020 | |
| Shire North American Group INC | $15.50 | 2019 | |
| Baxter Healthcare | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Warmoth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.